SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-035221
Filing Date
2024-09-06
Accepted
2024-09-06 08:45:11
Documents
15
Period of Report
2024-08-30
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 70901
2 ex3-1.htm EX-3.1 70360
3 ex3-2.htm EX-3.2 75167
  Complete submission text file 0001493152-24-035221.txt   427210

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rspi-20240830.xsd EX-101.SCH 3018
5 XBRL LABEL FILE rspi-20240830_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE rspi-20240830_pre.xml EX-101.PRE 24167
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3561
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 241283040
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)